Pro-Pharmaceuticals reports "promising" data

Pro-Pharmaceuticals Inc. of Newton reported "promising early data" from a Phase II trial of a colorectal cancer treatment.

The trial is for a first-line treatment of patients with metastatic, unresectable colorectal cancer who are unable to tolerate intensive chemotherapy, the company said.

Pro-Pharmaceuticals reported that three of seven evaluable patients in the test have experienced tumor shrinkage of greater than 30 percent; in addition, none of the patients in the test experienced severe side effects.
(By Chris Reidy, Globe staff)